» Articles » PMID: 38004046

How to Choose the Right Treatment for Membranous Nephropathy

Overview
Publisher MDPI
Specialty General Medicine
Date 2023 Nov 25
PMID 38004046
Authors
Affiliations
Soon will be listed here.
Abstract

Membranous nephropathy is an autoimmune disease affecting the glomeruli and is one of the most common causes of nephrotic syndrome. In the absence of any therapy, 35% of patients develop end-stage renal disease. The discovery of autoantibodies such as phospholipase A2 receptor 1, antithrombospondin and neural epidermal growth factor-like 1 protein has greatly helped us to understand the pathogenesis and enable the diagnosis of this disease and to guide its treatment. Depending on the complications of nephrotic syndrome, patients with this disease receive supportive treatment with diuretics, ACE inhibitors or angiotensin-receptor blockers, lipid-lowering agents and anticoagulants. After assessing the risk of progression of end-stage renal disease, patients receive immunosuppressive therapy with various drugs such as cyclophosphamide, steroids, calcineurin inhibitors or rituximab. Since immunosuppressive drugs can cause life-threatening side effects and up to 30% of patients do not respond to therapy, new therapeutic approaches with drugs such as adrenocorticotropic hormone, belimumab, anti-plasma cell antibodies or complement-guided drugs are currently being tested. However, special attention needs to be paid to the choice of therapy in secondary forms or in specific clinical contexts such as membranous disease in children, pregnant women and patients undergoing kidney transplantation.

Citing Articles

A review of progress on complement and primary membranous nephropathy.

Yu S, Sun J Medicine (Baltimore). 2024; 103(29):e38990.

PMID: 39029058 PMC: 11398747. DOI: 10.1097/MD.0000000000038990.


Membranous nephropathy: pathogenesis and treatments.

Wang M, Yang J, Fang X, Lin W, Yang Y MedComm (2020). 2024; 5(7):e614.

PMID: 38948114 PMC: 11214595. DOI: 10.1002/mco2.614.


Overlap of Scleroderma and Class V Lupus Nephritis: A Rare Autoimmune Confluence.

Reddy H, Kashiv P, Kumar S, Sejpal K, Acharya S Cureus. 2024; 16(3):e56990.

PMID: 38681456 PMC: 11046166. DOI: 10.7759/cureus.56990.

References
1.
von Haxthausen F, Reinhard L, Pinnschmidt H, Rink M, Soave A, Hoxha E . Antigen-Specific IgG Subclasses in Primary and Malignancy-Associated Membranous Nephropathy. Front Immunol. 2019; 9:3035. PMC: 6306563. DOI: 10.3389/fimmu.2018.03035. View

2.
Moroni G, Ponticelli C . Secondary Membranous Nephropathy. A Narrative Review. Front Med (Lausanne). 2020; 7:611317. PMC: 7744820. DOI: 10.3389/fmed.2020.611317. View

3.
El-Zoghby Z, Grande J, Fraile M, Norby S, Fervenza F, Cosio F . Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant. 2009; 9(12):2800-7. DOI: 10.1111/j.1600-6143.2009.02851.x. View

4.
Barbour S, Greenwald A, Djurdjev O, Levin A, Hladunewich M, Nachman P . Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2011; 81(2):190-5. DOI: 10.1038/ki.2011.312. View

5.
Chen M, Li H, Li X, Lu F, Ni Z, Xu F . Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci. 2010; 339(3):233-8. DOI: 10.1097/MAJ.0b013e3181ca3a7d. View